Clinical trial
Replicate Studies Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis
NCT05292872 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Replicate Studies Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 1, 2015
- Completion date
- December 31, 2021
- Enrollment
- 4,577 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary biliary cholangitis